Base de dados : LILACS
Pesquisa : D12.776.260.755.199 [Categoria DeCS]
Referências encontradas : 3 [refinar]
Mostrando: 1 .. 3   no formato [Detalhado]

página 1 de 1

  1 / 3 LILACS  
              next record last record
para imprimir
Texto completo SciELO Brasil
Texto completo
Id: lil-647752
Autor: Sun, Q.; Xiong, J.; Lu, J.; Xu, S.; Li, Y.; Zhong, X.P.; Gao, G.K.; Liu, H.Q..
Título: Secretory TAT-peptide-mediated protein transduction of LIF receptor α-chain distal cytoplasmic motifs into human myeloid HL-60 cells
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;45(10):913-920, Oct. 2012. ilus.
Idioma: en.
Resumo: The distal cytoplasmic motifs of leukemia inhibitory factor receptor α-chain (LIFRα-CT3) can independently induce intracellular myeloid differentiation in acute myeloid leukemia (AML) cells by gene transfection; however, there are significant limitations in the potential clinical use of these motifs due to liposome-derived genetic modifications. To produce a potentially therapeutic LIFRα-CT3 with cell-permeable activity, we constructed a eukaryotic expression pcDNA3.0-TAT-CT3-cMyc plasmid with a signal peptide (ss) inserted into the N-terminal that codes for an ss-TAT-CT3-cMyc fusion protein. The stable transfection of Chinese hamster ovary (CHO) cells via this vector and subsequent selection by Geneticin resulted in cell lines that express and secrete TAT-CT3-cMyc. The spent medium of pcDNA3.0-TAT-CT3-cMyc-transfected CHO cells could be purified using a cMyc-epitope-tag agarose affinity chromatography column and could be detected via SDS-PAGE, with antibodies against cMyc-tag. The direct administration of TAT-CT3-cMyc to HL-60 cell culture media caused the enrichment of CT3-cMyc in the cytoplasm and nucleus within 30 min and led to a significant reduction of viable cells (P < 0.05) 8 h after exposure. The advantages of using this mammalian expression system include the ease of generating TAT fusion proteins that are adequately transcripted and the potential for a sustained production of such proteins in vitro for future AML therapy.
Descritores: Citoplasma/metabolismo
Produtos do Gene tat/metabolismo
Subunidade alfa de Receptor de Fator Inibidor de Leucemia/metabolismo
-Cromatografia de Afinidade
Diferenciação Celular/genética
Eletroforese em Gel de Poliacrilamida
Vetores Genéticos
Produtos do Gene tat/genética
Subunidade alfa de Receptor de Fator Inibidor de Leucemia/genética
Limites: Animais
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME

  2 / 3 LILACS  
              first record previous record next record last record
para imprimir
Texto completo
Id: lil-444963
Autor: Vaags, A. K; Campbell, T. N; Choy, F. Y.
Título: HIV TAT variants differentially influence the production of glucocerebrosidase in Sf9 cells
Fonte: Genet. mol. res. (Online);4(3):491-495, 2005. ilus.
Idioma: en.
Projeto: Natural Sciences and Engineering Research Council.
Resumo: Gaucher disease, the most common lysosomal storage disorder, is currently treated with enzyme replacement therapy. This approach, however, is ineffective in altering the progression of neurodegeneration in type 2 and type 3 patients due to the difficulty of transferring the recombinant enzyme across the blood-brain barrier. Human immunodeficiency virus type 1 trans-activating transcriptional activator protein (HIV TAT) contains a protein transduction domain that can be added to a fusion protein partner to allow for transport of the partner across membranes. Consequently, we examined the creation, production, and secretion of fusion constructs containing glucocerebrosidase and either wild-type TAT or modified TAT in Sf9 cells. All three constructs exhibited successful expression, with wild-type TAT chimeras showing lower levels of expression than modified TAT chimeras.
Descritores: Glucosilceramidase/biossíntese
Produtos do Gene tat/metabolismo
-Linhagem Celular
Células Cultivadas
Doença de Gaucher/metabolismo
Doença de Gaucher/terapia
Membrana Celular/metabolismo
Produtos do Gene tat/genética
Transcrição Genética
Transdução Genética
Transporte Proteico/genética
Limites: Humanos
Responsável: BR1.1 - BIREME

  3 / 3 LILACS  
              first record previous record
para imprimir
Id: lil-258503
Autor: Castagnino, Juan Miguel.
Título: Enfoque innovador en el tratamiento del SIDA / Innovating approach in tthe treatment of the AIDS
Fonte: Acta bioquím. clín. latinoam;33(4):397-8, dic. 1999.
Idioma: es.
Descritores: Síndrome de Imunodeficiência Adquirida/imunologia
-Produtos do Gene nef
Produtos do Gene tat
Síndrome de Imunodeficiência Adquirida/epidemiologia
Síndrome de Imunodeficiência Adquirida/prevenção & controle
Limites: Humanos
Tipo de Publ: Editorial
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco

página 1 de 1

Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde